Raymond James Sticks to Its Buy Rating for AngioDynamics (ANGO)

Raymond James analyst Jayson Bedford maintained a Buy rating on AngioDynamics (ANGOResearch Report) yesterday. The company’s shares closed last Wednesday at $23.60, close to its 52-week high of $24.50.

According to TipRanks.com, Bedford is a 5-star analyst with an average return of 16.4% and a 72.2% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Edwards Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AngioDynamics with a $24.00 average price target.

See today’s analyst top recommended stocks >>

Based on AngioDynamics’ latest earnings release for the quarter ending February 28, the company reported a quarterly revenue of $71.18 million and GAAP net loss of $3.54 million. In comparison, last year the company earned revenue of $69.78 million and had a GAAP net loss of $5.71 million.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANGO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.